Premium
HIV positive men with Non‐Alcoholic Steatohepatitis (NASH) have altered hepatic fatty acid composition
Author(s) -
Arendt Bianca Maria,
Mohammed Saira S.,
Aghdassi Elaheh,
Salit Irving E.,
Guindi Maha,
Ma David W. L.,
Allard Johane P.
Publication year - 2008
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.22.2_supplement.717
Subject(s) - steatohepatitis , linoleic acid , medicine , eicosapentaenoic acid , arachidonic acid , docosahexaenoic acid , polyunsaturated fatty acid , steatosis , endocrinology , chemistry , fatty liver , fatty acid , biochemistry , disease , enzyme
Hepatic fatty acid (FA) composition might play a role in the development of simple hepatic steatosis (SS) to NASH. Aim was to compare hepatic FA composition in HIV+ men with NASH to those with SS. METHOD: Prospective, cross‐sectional study in 19 HIV+ men (6 SS, 13 NASH). Hepatic FA composition (% of total lipid, gas chromatography) and lipid peroxidation (LPO, testkit), blood biochemistry, anthropometry, medical history and dietary intake were assessed. Mann‐Whitney‐U test was used, p<0.05 is considered significant. RESULTS: HIV‐NASH had lower arachidonic acid (AA) (mean±SEM: 1.4±0.4 vs. 3.0±0.5%) and docosahexaenoic acid (DHA) (0.37±0.86 vs. 0.86±0.10%) compared to HIV‐SS. Metabolite/precursor ratio was significantly reduced for n‐6 PUFA (AA/linoleic acid: 0.24±0.04 vs. 0.45±0.12) and a trend was seen for n‐3 ((eicosapentaenoic acid +DHA)/linolenic acid: 1.4±0.3 vs. 3.0±0.7; p=0.062). HIV‐NASH were older (47±2 vs. 40±2 y), but LPO, body mass index, diet and other variables were not different. Similar results were found when HIV‐NASH were compared to healthy controls. In addition, n6/n3 ratio was increased (HIV‐NASH: 9.1±1.4 vs. controls: 5.4±0.5). CONCLUSION: HIV+ men with NASH have reduced long‐chain PUFA and metabolite/precursor ratios in hepatic total lipids, suggesting changes in FA metabolism. Other factors do not seem to play a role. Funded by Ontario HIV Treatment Network.